Investment Rating - The report assigns a "Buy" rating to Yanzhou Coal Mining Company (兖矿能源) with a target price of 16.27 CNY per share [1][5]. Core Insights - The report anticipates that the company's net profit attributable to shareholders will be 9.448 billion, 12.019 billion, and 14.171 billion CNY for the years 2025-2027, with corresponding EPS of 0.94, 1.20, and 1.41 CNY, reflecting a year-on-year growth of -39.61%, 27.21%, and 17.91% respectively [1][20]. - The coal market is expected to maintain a stable price range of 700-800 CNY per ton from 2025 to 2027, despite market concerns about oversupply [2][16]. - The company has substantial coal reserves of 464 billion tons and a recoverable reserve of 60 billion tons, positioning it among the top coal producers in China [2][59]. - The company has a strong track record of cash dividends, with an average payout ratio of 49.82% since its listing, and a projected payout ratio of 53.58% for 2024 [2][20]. Summary by Sections Financial Performance - The company is projected to achieve revenues of 120.47 billion, 127.92 billion, and 131.39 billion CNY for 2025-2027, with growth rates of -13.4%, 6.2%, and 2.7% respectively [3][20]. - The net profit for 2024 is expected to be 15.644 billion CNY, down 23.9% from the previous year, while the 2025 net profit is projected to decline significantly before recovering in subsequent years [3][20]. Business Overview - Yanzhou Coal Mining Company operates as a comprehensive energy operator with a diverse business layout, including mining, high-end chemical materials, and renewable energy [27]. - The coal segment is expected to contribute 66% of total revenue and 83% of total profit in 2024, highlighting its critical role in the company's financial health [12][29]. Market Dynamics - The report indicates that the coal supply-demand balance is expected to remain stable, with domestic coal production projected to stabilize around 38.5-39 billion tons from 2025 to 2027 [55]. - The demand for coal is anticipated to remain robust due to the ongoing reliance on thermal power generation, which still accounts for a significant portion of electricity production in China [48][49].

Group 1: Company Overview - The report covers Damai Entertainment (1060.HK), a leading platform in live entertainment, driven by ticketing and IP derivatives [1][6][8] - The company is positioned in a high-growth sector, benefiting from the recovery and structural upgrade of offline entertainment consumption [1][8] - Expected adjusted net profits for FY26-28 are projected at 1.06 billion, 1.35 billion, and 1.58 billion CNY respectively [1][8] Group 2: Industry Insights - The live performance market is experiencing a significant increase, with ticket sales for large concerts expected to exceed 26 billion CNY in 2024, a year-on-year growth of 78.1% [6] - The demand for live entertainment is driven by both personal enjoyment and social needs, with an increase in repeat attendance [6] - The supply side is expanding with diversification in lower-tier cities and various performance categories [6] Group 3: IP Business - Alibaba's IP licensing platform, Aliyu, is a leading player in the market, with a projected GMV of 4.1 billion USD in 2024 [7] - The company is enhancing its collaboration with top IPs, which is expected to contribute significantly to revenue growth [7] - The film industry is still in a recovery phase, with a total box office of 29.23 billion CNY in the first half of 2025, reflecting a year-on-year increase of 22.91% [7] Group 4: Company Financials - Sinopec Engineering (02386.HK) is highlighted as a leading energy and chemical engineering firm with strong technical capabilities and a solid financial performance [10][12] - The company has a high dividend payout ratio, with a dividend yield exceeding 5%, providing stable returns for investors [10][12] - Expected target price for 2026 is set at 9.50 HKD per share, based on a 13x PE ratio [10] Group 5: Market Trends - The petrochemical industry is facing revenue stability but profit pressures, with a slight revenue decline of 2.6% year-on-year in H1 2025 [11] - The trend of "reducing oil and increasing chemicals" is evident, with a 9.94% year-on-year increase in ethylene consumption [11] - Global refining capacity continues to grow, particularly in the Middle East and Asia-Pacific regions, with a projected capital expenditure of 153.35 billion USD in 2024 [11] Group 6: Aviation Sector - Bank of China Aviation Leasing (02588.HK) is positioned to benefit from the rising aviation industry and the ongoing interest rate cut cycle [14][15] - The company ranks fifth globally with a fleet of 483 aircraft, poised to gain from increased revenues as the aviation market recovers [14][15] - Expected total revenue for 2025-2027 is projected at 2.63 billion, 2.85 billion, and 2.94 billion USD, with net profits of 761 million, 894 million, and 964 million USD respectively [16] Group 7: Medical Sector - Weisi Medical (688580.SH) is experiencing steady growth, with projected net profits of 133 million, 165 million, and 184 million CNY for 2025-2027 [4][18] - The company focuses on rehabilitation as its core business while expanding into aesthetic and urology sectors [18][19] - The company emphasizes product innovation in non-invasive brain-machine interfaces, aiming to create a comprehensive neuro-rehabilitation system [19]

Investment Rating - The report assigns a "Buy" rating to Sinopec Engineering (02386.HK) with a target price of HKD 9.50 per share based on a 2026 PE of 13 times [1][5]. Core Insights - Sinopec Engineering is one of the largest energy and chemical engineering companies in China, with leading technical capabilities and strong backing from its parent company, Sinopec Group. The company is expanding its overseas business, contributing to performance growth. Additionally, it has a solid financial performance with a high dividend payout ratio, offering a stable yield of over 5% for investors [1][18]. Company Overview - Sinopec Engineering provides comprehensive services across the entire industry chain and lifecycle, focusing on refining and petrochemical engineering. It has a strong international competitive edge and a history of over 70 years [23][26]. - The company is backed by Sinopec Group, which holds a 62.52% stake, ensuring a stable business foundation [30][34]. Industry Analysis - The petrochemical industry is experiencing pressure on profits, with a slight revenue decline of 2.6% year-on-year in H1 2025, while total profits fell by 10.3%. However, the demand for petrochemical products remains, driven by the "reduce oil, increase chemicals" trend [2][17]. - Policy support for coal chemical development is evident, with significant investments planned in Xinjiang, exceeding 900 billion [2][17]. Financial Performance - For H1 2025, Sinopec Engineering reported a revenue increase of 10.14% year-on-year and a net profit increase of 4.83%. The company has maintained a dividend payout ratio above 63% over the past four years, with a current dividend yield of 5.33% [3][4]. - The company's revenue is projected to grow steadily, with estimates of 70.66 billion in 2025 and 78.10 billion in 2026, reflecting a growth rate of 10.06% and 10.53% respectively [4][18]. Growth Drivers - The company has seen a 24.35% increase in new contracts signed in Q1-Q3 2025, with a backlog of contracts amounting to 215.47 billion, which is 3.36 times the expected revenue for 2024 [3][39]. - The overseas revenue for H1 2025 increased by 92% year-on-year, indicating strong growth potential in international markets [3][39].

Investment Rating - The report assigns an "Accumulate" rating to BOC Aviation (02588.HK) [6] Core Views - BOC Aviation is positioned to benefit from the rising aviation industry and the Federal Reserve's interest rate cuts, with a fleet of 483 aircraft, ranking fifth globally among aircraft leasing companies. The company is expected to see revenue growth from its global airline customer base and a decrease in funding costs due to lower interest rates, leading to an expansion of profit margins [2][6] - The aviation market is recovering strongly post-pandemic, with global available seat kilometers (ASK) returning to pre-pandemic levels by mid-2025. A shortage of aircraft supply due to delivery delays from Boeing and Airbus is expected to drive rental prices upward [2][3] Summary by Sections Company Overview - BOC Aviation, a leading aircraft leasing company backed by Bank of China, operates in 46 countries and regions, serving 88 airlines. The company has shown resilience and growth since its establishment in 1993 and its listing in Hong Kong in 2016 [22][23] Industry Analysis - The aviation leasing market is characterized by high concentration, with the top 20 companies holding a significant market share. The industry is currently in a recovery phase, with demand for air travel increasing, particularly in Europe and North America, while the Asia-Pacific region is expected to drive future growth [36][39][43] Competitive Advantages - BOC Aviation boasts a young fleet and long-term lease agreements, providing cost and liquidity advantages. The company is dynamically adjusting its debt structure to optimize financing costs, which are expected to decline as interest rates fall [3][12] Financial Projections - Revenue projections for BOC Aviation from 2025 to 2027 are estimated at $26.34 billion, $28.54 billion, and $29.39 billion, with corresponding net profits of $7.61 billion, $8.94 billion, and $9.64 billion. The earnings per share (EPS) are projected to be 8.53, 10.01, and 10.80 HKD respectively [4][12][13] Valuation and Target Price - The report suggests a target price of 84.37 HKD for BOC Aviation, based on a price-to-book (PB) ratio of 1.1 times, reflecting the company's strong position in the recovering aviation market and the anticipated decrease in funding costs [16]

公司深度研究 | 大麦娱乐 现实娱乐头部平台，演出票务与 IP 衍生双轮驱动 证券研究报告 2025 年 12 月 25 日 大麦娱乐（1060.HK）首次覆盖 演出：高景气赛道稳居龙头地位，内容+出海+品类驱动增长。现场演出市场 呈现"量价齐升"高景气度，据中国演出行业协会，2024 年大型演唱会票 房超 260 亿元，同比增长 78.1%。我们看好现场娱乐高景气度的持续性，需 求端，悦己与社交需求共振，多次观演比例提升；供给端，中低线城市与品 类多元化持续扩容。大麦稳居演出票务第一梯队，先发优势强，壁垒深厚， 高市占率的背后，是近 20 年的行业深耕，对上下游的深度整合，以及用户 消费习惯的培养与心智的养成。往后看，一方面，大麦受益于国内演出市场 的高景气度，另一方面，内容+出海+品类拓展亦打开向上空间。 IP：阿里鱼领跑授权蓝海，深化头部 IP 合作贡献业绩弹性。阿里鱼，全球 第六、中国第一大授权代理商，据 License Global，2024 年 GMV 达 41 亿 美元，以"IP2B2C"模式构建竞争壁垒，通过双边网络效应连接三丽鸥、 宝可梦等数百个优质 IP 与 10 万+淘系商家，全链条沉淀 ...

Investment Rating - The investment rating for the company is "Accumulate" [4]. Core Insights - The company achieved a revenue of 326 million yuan in the first three quarters of 2025, representing a year-on-year growth of 11.58%, and a net profit attributable to the parent company of 102 million yuan, up 30.68% year-on-year [1][4]. - The core business of rehabilitation is steadily growing, while new emerging businesses in aesthetic medicine and urology are being developed, creating a multi-layered business structure [1]. - The mental rehabilitation business is benefiting from policy support and market demand, maintaining double-digit growth, while the pelvic floor rehabilitation business is experiencing single-digit growth due to product upgrades [1][2]. Financial Performance Summary - For the first three quarters of 2025, the company reported a revenue of 326 million yuan, with a net profit of 102 million yuan and a non-recurring net profit of 94 million yuan [1]. - The company expects net profits for 2025, 2026, and 2027 to be 133 million yuan, 165 million yuan, and 184 million yuan, respectively, with year-on-year growth rates of 30.1%, 24.0%, and 11.8% [2][3]. - The sales, management, and R&D expense ratios for the first three quarters of this year were 18.77%, 10.03%, and 9.74%, respectively, showing a decrease compared to the previous year [2].

晨会纪要 证券研究报告 2025 年 12 月 25 日 核心结论 分析师 【医疗器械】IVD 体外诊断相关医疗器械行业报告：IVD 国内短期承压，头 部企业积极出海 建议关注公司：迈瑞医疗（300760.SZ，已覆盖）、新产业（300832.SZ）、 安图生物（603658.SH，已覆盖）、亚辉龙（688575.SH）、迪瑞医疗 （300396.SZ）、艾德生物（300685.SZ）等 风险提示：行业政策变化风险、新产品研发注册风险、技术替代风险、行业 竞争加剧风险、地缘政治等风险 【医药生物】健康元（600380.SH）首次覆盖报告：呼吸龙头再起航，创新 +国际化开启成长新篇章 盈利预测与评级：预计 2025-2027 年公司实现营收 158.11/170.17/182.73 亿元，同比增长 1.2%/7.6%/7.4%，归母净利润 14.66/15.72/17.09 亿元，同 比增长 5.7%/7.3%/8.7%。基于公司主业集采影响出清、创新管线即将步入 收获期，首次覆盖给予"买入"评级。 风险提示：市场竞争加剧，产品销售不及预期；新药研发进度不及预期；产 品集采降价超预期。 【北交所】北交所市场点评 ...

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies [27]. Core Insights - The North Exchange A-shares trading volume reached 21.69 billion yuan on December 23, 2025, an increase of 1.215 billion yuan from the previous trading day, with the North Exchange 50 index closing at 1439.94, down 0.64% [2][9]. - The North Exchange specialized and innovative index closed at 2413.60, down 1.05% [2][9]. - Among 286 companies listed on the North Exchange, 33 saw an increase in stock price, while 253 experienced a decline [2][17]. - The report highlights that the hard technology sector, including semiconductors and AI computing, was the main focus of A-share trading, but this did not effectively transmit to the North Exchange [4]. Summary by Sections Market Review - On December 23, the North Exchange A-shares trading volume was 21.69 billion yuan, with a PE_TTM of 60.37 times [9][15]. - The North Exchange 50 index decreased by 0.64%, while the specialized and innovative index fell by 1.05% [2][9]. Stock Performance - The top five gainers included: - Rongyi Precision (up 8.9%) - Hongxi Technology (up 7.9%) - Shuguang Digital Innovation (up 6.8%) - Tonghui Electronics (up 6.5%) - Tianhong Lithium Battery (up 6.4%) [2][17]. - The top five losers were: - Hanxin Technology (down 14.9%) - Xingchen Technology (down 13.3%) - *ST Guandao (down 12.1%) - Tianye Co. (down 11.7%) - Ruixing Co. (down 9.1%) [2][17]. Important News - Beijing issued the first batch of L3 level special license plates for autonomous driving vehicles on highways, allowing dynamic driving tasks under certain conditions [3][20]. - The National Development and Reform Commission and the National Energy Administration aim for a total installed capacity of 15 million kilowatts for solar thermal power by 2030, with costs comparable to coal power [3][20]. Company Announcements - Changjiang Energy Technology plans to use up to 100 million yuan of temporarily idle raised funds to purchase safe and liquid investment products [21]. - Meideng Technology announced the use of 10 million yuan of idle self-owned funds for cash management [21][24].

Investment Rating - The industry rating is "Overweight" and has been maintained from the previous rating [4] Core Insights - The global IVD market is projected to grow from USD 66.7 billion in 2018 to USD 186.1 billion by 2030, with a CAGR of 8.9% [12] - The Chinese IVD market is expected to increase from RMB 71.3 billion in 2018 to RMB 415.2 billion by 2030, with a CAGR of 15.8%, significantly outpacing the global average [13] - The immunodiagnostics market in China is experiencing rapid growth, with a market size increase from RMB 37.3 billion in 2021 to RMB 50.3 billion in 2023, reflecting a CAGR of 16.13% [16] - The POCT market is also expanding quickly, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023, with a CAGR of 19.52% [20] - The molecular diagnostics market, despite a decline from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, still shows potential with a market size exceeding RMB 10 billion when excluding emergency-related factors [25] Summary by Sections IVD Market Outlook - The IVD industry began in the 1950s and has seen significant growth due to advancements in medical technology and increasing health demands [11] - The Chinese IVD market has diversified into various diagnostic technologies, including biochemical, immunological, POCT, molecular, and pathological diagnostics [15] Immunodiagnostics Market - The immunodiagnostics market is the largest segment in China's IVD market, accounting for over 40% in 2023 [15] - The market is expected to face some deceleration due to price reductions from centralized procurement policies [16] Biochemical Diagnostics Market - The biochemical diagnostics market in China grew from RMB 17.1 billion in 2021 to RMB 19 billion in 2023, with a CAGR of 5.41% [19] - Domestic products dominate this market with over 70% market share [19] POCT Market - The POCT market is driven by convenience and increased demand for home testing, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023 [20] Molecular Diagnostics Market - The molecular diagnostics market has faced challenges, declining from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, primarily due to reduced demand post-pandemic [25] Pathogen Microbiology Market - The pathogen microbiology diagnostics market in China is projected to grow from RMB 16.82 billion in 2018 to RMB 90.27 billion by 2030, with a CAGR of 15.0% [30]

公司深度研究 | 健康元 呼吸龙头再起航，创新+国际化开启成长新篇章 健康元（600380.SH）首次覆盖报告 大型综合医药集团，创新+国际化开启新篇章。公司始创于 1992 年，保健品 业务起家，通过收并购不断开拓商业版图，经过 30 余年逐步发展为大型综 合医药集团。近年来，公司加快布局国际化及创新转型，一方面推动海外生 产基地建设，同时通过合作引进等方式快速丰富研发管线，聚焦呼吸常见疾 病，同时拓展镇痛、抗感染等领域布局。 制剂集采压力出清，新品放量助力主业拐点向上。近年来受艾普拉唑系列产 品、盐酸左沙丁胺醇吸入溶液等大单品降价影响，公司主业短暂承压，目前 核心产品降价压力基本出清，后续随着妥布霉素吸入溶液、玛帕西沙韦等新 品陆续放量，公司主业有望拐点向上。 加快创新管线布局，聚焦呼吸大适应症。多年深耕呼吸领域，近年来随着公 司创新转型进程加速推进，公司通过合作引进快速扩充在研管线，覆盖支气 管扩张、流感、COPD 等呼吸常见适应症。目前改良新药妥布霉素吸入溶液 以及流感新药玛帕西沙韦胶囊已获批，另外 TSLP 单抗、MABA 双靶点吸入 溶液、PREP 抑制剂等核心药物已进入 2 期临床。 丽珠集团： ...